Guidelines for Diagnosis and Management of Chronic Pulmonary Aspergillosis

Classification and Diagnostic Criteria

• Pulmonary aspergillosis is divided into distinct clinical entities; diagnosis requires a combination of imaging, immunological evidence, and a minimum symptom duration of ≥ 3 months to separate chronic from invasive disease【1】.

• Chronic Pulmonary Aspergillosis (CPA) is diagnosed only when all of the following are present for at least 3 months: (1) one or more pulmonary cavities or nodules on thoracic imaging, (2) direct microbiological evidence (culture/microscopy) or a demonstrable immunological response to Aspergillus, and (3) exclusion of alternative diagnoses【1】.

• Elevated Aspergillus‑specific IgG antibodies (precipitins) are found in > 90 % of CPA patients and represent the most sensitive microbiological test【1】.

• Simple (single) aspergilloma is defined by a solitary fungal ball within a single cavity, minimal or absent symptoms, no radiological progression over ≥ 3 months, and confirmation by positive Aspergillus serology when the ball is visualised【1】.

• Chronic Cavitary Pulmonary Aspergillosis (CCPA) is the most common CPA form, characterized by one or more cavities (thin‑ or thick‑walled), possible aspergillomas or intraluminal material, significant systemic symptoms (cough, dyspnea, hemoptysis, weight loss, fatigue), and overt radiological progression (new cavities, increasing infiltrates, or fibrosis)【1】.

• Chronic Fibrosing Pulmonary Aspergillosis (CFPA) represents end‑stage CCPA with severe fibrotic destruction of at least two lobes and marked loss of lung function【1】.

• Aspergillus nodules may be solitary or multiple, cavitated or solid, mimic tuberculosis or malignancy, and require histology showing absence of tissue invasion for definitive diagnosis【1】.

• Subacute Invasive Aspergillosis (SAIA) develops over 1–3 months in moderately immunocompromised patients (e.g., chronic corticosteroids > 10 mg prednisolone daily, diabetes, liver disease, malnutrition, COPD) and should be managed as invasive disease【1】.

• Distinguishing features of SAIA include rapid progression (1–3 months), variable radiology (cavitation, nodules, consolidation), concurrent detection of Aspergillus‑specific IgG and circulating galactomannan, hyphal invasion on histopathology, and the need for invasive‑aspergillosis treatment protocols【1】.

Diagnostic Workup

Imaging

• High‑resolution CT is essential; it demonstrates mobile intracavitary fungal balls (aspergillomas) as mobile masses within cavities【1】.

Microbiological Confirmation

• CPA can be confirmed by any of the following (after excluding alternatives):

Critical Differential Diagnoses

• Mycobacterial infection (tuberculosis or non‑tuberculous mycobacteria) is the principal alternative and may coexist with CPA; dual infection is frequent and linked to poorer outcomes【2】.
• Mandatory mycobacterial testing in cavitary disease includes sputum smear for acid‑fast bacilli, nucleic‑acid amplification, and culture【2】.
• Endemic fungal infections to exclude (based on geography/travel) are chronic cavitary histoplasmosis, coccidioidomycosis, and paracoccidioidomycosis; differentiation relies on specific antibody/antigen assays and culture【2】.
• Other important differentials include necrotizing lung cancer, pulmonary infarction, vasculitides, and rheumatoid nodules【2】.

Management

Simple Aspergilloma

• Surgical excision (preferably video‑assisted thoracic surgery) is recommended when technically feasible【1】.
• Antifungal therapy is reserved for incompletely resected lesions or multiple nodules, with careful follow‑up【1】.

Chronic Cavitary Pulmonary Aspergillosis (CCPA)

• Long‑term oral antifungal therapy is advised to improve overall health, control respiratory symptoms, arrest hemoptysis, and prevent disease progression【1】.
• First‑line agents include voriconazole (loading 6 mg/kg IV q12 h × 2, then 4 mg/kg IV q12 h or 200 mg PO BID) and itraconazole as an accepted alternative for prolonged treatment【1】.
• Minimum initial treatment duration is 4–6 months, extending to ≥ 9 months if response is limited; indefinite suppressive therapy may be required for persistent CCPA【1】.

Monitoring Requirements

• Therapeutic drug monitoring of azole serum concentrations is essential【1】.
• Vigilance for drug interactions, especially rifampicin (used for concurrent TB), is required with dose adjustments and monitoring【1】.
• Regular assessment for azole‑related toxicities (hepatic, visual, dermatologic) should be performed【1】.

Hemoptysis Management

• New or worsening hemoptysis may indicate therapeutic failure or antifungal resistance【1】.
• Management hierarchy: oral tranexamic acid for mild‑moderate bleeding, bronchial artery embolization for severe hemoptysis, and surgical resection only for localized disease refractory to other measures【1】.

Common Pitfalls

• Do not base CPA diagnosis solely on a positive sputum culture, as Aspergillus colonisation is common (no citation needed).
• Always obtain mycobacterial studies in cavitary lung disease to avoid missing concurrent infection【2】.
• Do not apply the 3‑month duration criterion loosely; symptom progression within 1–3 months suggests SAIA and warrants invasive‑aspergillosis treatment protocols【1】.
• Therapeutic drug monitoring for azoles must not be omitted because of variable bioavailability and frequent toxicity【1】.

Guideline Summary for Airway Aspergillosis (European Respiratory Society)

Diagnostic Criteria and Imaging

• Chronic cavitary pulmonary aspergillosis (CCPA) is the predominant form of chronic pulmonary aspergillosis in patients with pre‑existing structural lung disease; diagnosis requires pulmonary cavities persisting ≥ 3 months with progressive symptoms and radiologic worsening 3.
• A minimum disease duration of 3 months is essential to differentiate CCPA from more aggressive invasive disease 3.
• High‑resolution CT in CCPA typically demonstrates irregular‑walled cavities, often containing a fungal ball (aspergilloma) and showing progressive enlargement 3.
• Subacute invasive aspergillosis (SAIA) develops over 1–3 months in moderately immunocompromised individuals (e.g., chronic corticosteroid use, diabetes, liver disease, malnutrition) 3.
• In SAIA, both Aspergillus‑specific IgG antibodies and circulating antigen are usually detectable in serum 4.
• Histopathology in SAIA reveals hyphal invasion of lung parenchyma 4.

Microbiological Findings

• Respiratory cultures are positive for Aspergillus in 56–81 % of chronic pulmonary aspergillosis cases 5.
• Isolation of Aspergillus from sputum alone does not confirm infection because the organism is ubiquitous; detection in bronchoscopic specimens is far more indicative of true disease [5][4].

Differential Diagnosis and Co‑Infections

• Mycobacterial infection (tuberculosis or non‑tuberculous mycobacteria) is the principal alternative diagnosis for cavitary lung lesions and may coexist with CPA 4.
• Endemic fungal infections (histoplasmosis, coccidioidomycosis, paracoccidioidomycosis) should be distinguished by specific antibody or antigen testing and culture 4.
• Concurrent bacterial superinfection of persistent cavities (e.g., Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa) is common and warrants appropriate antibacterial therapy 4.
• Dual infections (mycobacterial plus Aspergillus) are frequent and are associated with poorer outcomes 4.

Antifungal Treatment

• Voriconazole is recommended as first‑line therapy for CCPA, administered with a loading dose of 6 mg/kg IV every 12 h for two doses, followed by maintenance dosing of 4 mg/kg IV every 12 h or 200 mg orally twice daily 6.
• Itraconazole is an accepted alternative for CCPA, requiring long‑term therapy to achieve disease control [6][7].
• SAIA and invasive pulmonary aspergillosis in severely immunocompromised patients should be treated aggressively with voriconazole or other mold‑active agents according to established invasive aspergillosis protocols 4.

Surgical Management

• Simple aspergilloma (a solitary fungal ball in a pre‑existing cavity without progression) is best managed by surgical resection when the patient is a suitable operative candidate 6.

Evidence Strength

• All recommendations above are based on expert consensus and observational data reported in the European Respiratory Journal (2016); the evidence is classified as moderate for diagnostic criteria and imaging, moderate for microbiological yield, and moderate for antifungal and surgical management.

Clinical Forms of Aspergillosis

Chronic Pulmonary Aspergillosis (CPA)

• The European Respiratory Society recommends that CPA be diagnosed in non-immunocompromised patients with prior or current structural lung disease and at least 3 months of symptoms 8, 9, 10
• Simple aspergilloma is characterized by a single pulmonary cavity containing a fungal ball with minimal or no symptoms and no radiological progression over at least 3 months, requiring serological or microbiological evidence of Aspergillus species 9, 10, 11
• Chronic cavitary pulmonary aspergillosis (CCPA) is the most common form of CPA, characterized by one or more pulmonary cavities with significant pulmonary and systemic symptoms and overt radiological progression over at least 3 months 8, 9, 10, 12
• Chronic fibrosing pulmonary aspergillosis (CFPA) is a severe form of CPA, characterized by fibrotic destruction of at least two lobes of lung, leading to major loss of lung function 8, 9, 10
• Aspergillus nodule is an unusual form of CPA, characterized by one or more nodules that do not usually cavitate, representing an unusual form of CPA 8, 9, 10

Invasive Aspergillosis

• Invasive aspergillosis occurs in severely immunocompromised patients and presents as necrotizing pneumonia or tracheobronchitis, with primary symptoms including fever, cough, dyspnea, chest pain, hemoptysis, and hypoxemia 13
• CT findings include the "halo sign" and "air crescent sign" with cavitation as disease progresses 13

Subacute Invasive Aspergillosis (SAIA)

• SAIA is a more rapidly progressive infection occurring over 1-3 months in mildly to moderately immunocompromised patients, with variable radiological features including cavitation, nodules, and progressive consolidation 8, 9, 10, 12
• Biopsy shows hyphae invading lung tissue, and positive Aspergillus galactomannan antigen in blood or respiratory fluids 8, 9, 10

Important Clinical Pitfalls

• The duration criterion of 3 months is critical for distinguishing CPA from invasive or subacute forms, with symptoms present for less than 3 months suggesting SAIA or invasive disease requiring more aggressive management 8, 9, 10
• Aspergillus serology (IgG/precipitins) is elevated in over 90% of CPA patients but is typically negative in invasive disease 12, 14